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ABSTRACT 
Background: HIV/AIDS has become a major public health problem, with host genetic factors such as 
CCR2-V641 and CCR5-∆32 genes determining the probability of acquiring it and the rate of disease 
progression. The frequency of these genes is not well described in high HIV endemic areas like 
Zimbabwe among pregnant women. Yet this information is important in the design and development 
of HIV drugs and vaccines.  
Aim:  To determine and compare the prevalence of  CCR5-∆32  and CCRV64I genes in HIV positive 
and HIV negative population of pregnant women from Harare, in Zimbabwe. 
Design: A cross-sectional study of CCR5- ∆32 and CCR2V641 chemokine co-receptors in 76 HIV 
positive and 166 HIV negative populations of pregnant women. 
Procedures:  DNA was extracted from sera samples using the Boom and co-workers (1990) method. 
SYBR green technology and melting curve analyses were carried out on an Applied Biosystems Step 
OneTM Plus Real-time PCR machine while FRET technology  and a Light Cycle TM technology real-
time PCR machine were used to determine the frequency of CCR5-∆32 and CCR2V641 respectively.  
Data analysis: Data was entered and analysed using a Statistical Package for Social Sciences (SPSS) 
version 16 (SPSS, IL, USA).  Chi-square ( ᵪ2  )  tests and relative risks (RR) for CCR5-∆32 and 
CCR2V641 chemokine co-receptors were used to assess if there was any association between these 
host genes and HIV infection.  Univariate analysis was also used. Notably multivariate regression 
analysis was used to control for confounders. 
Results: The proportion of pregnant  women with the  homozygous CCR2V64I gene  was 24.38%  
and this gene was two  times more  associated with HIV infection than in those without it  ( RR= 2.32,  
95% CI-1.38-3.92). No CCR5-∆32 deletion was detected in the studied population. 
Conclusion: The homozygous CCR2V64I gene and STIs were more prevalent in HIV infected 
pregnant women than in uninfected pregnant women and no homozygous CCR5-∆32 gene was 
detected in this study. 
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CHAPTER 1: INTRODUCTION 
1.1 Overview of the HIV epidemic 
Human Immunodeficiency Virus type 1 (HIV-1) continues to be a significant cause of 
mortality and morbidity in the world (Kaul, Makadzange & Rowland-Jones, 2000), with a 
disproportionate transmission and distribution among different regions. According to 
UNAIDS and the World Health Organization (2008b), in 2007 close to 1.5 million pregnant 
women were infected. Such pregnancies in HIV infection has resulted in over 250 000 
children dying from the epidemic, leaving two million of them living with the HIV infection 
(UNAIDS, 2008b). In Africa, the HIV epidemic has been heterogeneously distributed, with 
Sub-Saharan Africa (SSA) being one of the most heavily affected regions.  The region is host 
to five of the leading countries in HIV infection in the world. Women in this region constitute 
close to 60% of the total number of infected people (UNAIDS, 2008c). Because of this the 
number of infected children is expected to increase. 
In Zimbabwe HIV/AIDS remains a major public health problem as the country is still rated 
among the top five countries hardest hit by the epidemic in the world (UNAIDS, 2008a). 
According to UNAIDS (2008a), close to 15 % of the total population of 14 million was 
infected with the HIV/AIDS in 2007 and 52 000 of them being pregnant women living with 
HIV.  By 2007 close to 120 000 children were living with HIV in Zimbabwe (UNAIDS, 
2008a), most of whom became infected through mother-to-child transmission.  
Although there has been a disproportionate transmission and distribution of HIV epidemic in 
the world, with alarming rates in SSA, currently there is very little explanation for this 
observation (Martinsoni, Chapman, Rees, Liu & Clegg, 1997). Martinsoni and co-workers 
(1997) suggest that the distribution pattern of the rate and severity of the HIV epidemic may 
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be indicative of greater underlying susceptibility to the virus in certain populations, which 
may be attributable to certain ubiquitous factors such as host genetics.  
Sullivan and collaborators (2001) note that certain host genetic factors could have an impact 
on the heterosexual transmission of HIV epidemics. This observation has been documented 
by Rowland-Jones (1998) who notes that despite multiple sexual exposures to HIV-1, some 
individuals remained HIV negative. On the other hand the discovery of long-term non-
progressors (LTNP) in HIV infection provides a unique opportunity for further investigations 
into the role of host genetic factors in the progression of HIV infection to AIDS. The 
mechanism underlying this resistance to HIV infection remains unclear, although multiple 
factors have been hypothesized to be responsible for the pathogenesis of the HIV.  
Mounting evidence now suggest that HIV-1 infects the target cells using the CD4 cells 
receptor in conjunction with co-receptor molecules. Among the various chemokine co-
receptors that support virus entry are the chemokine co-receptor 5 (CCR5) and the CX 
chemokine co-receptor 4 (CXCR4).These have been identified as the major co-receptor of 
macrophage-tropic non-syncytium inducing (NSI) and T-cell tropic syncytium-inducing (SI) 
primary isolates, respectively (Ometto, Zanchetta, Mainardi, Salvo, Garcia-Rodriguez & 
Gray, 2000). It has been further demonstrated that the majority of NSI isolates utilize only 
CCR5, whereas most SI isolates, besides CXCR4, also use additional co-receptors like CCR2 
among others to enter target cells (Ometto  et al., 2000). 
Mutations in CCR5 and CXCR4 have either influenced the probability of acquiring HIV 
infection or have affected the rate of disease progression, in infected adults (Kostrikis, 
Neumann, Thomson, Korber, McHardy & Karanicolas, 1999) or infants (Misrahi, Teglas, 
Burgard, Mayaux, Rouzioux & Delfraissy, 1998). A 32-nucleotide deletion in CCR5, the 
CCR5-∆32 allele, leads to the translation of a defective CCR5 protein. This protein has been 
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identified as a natural genetic polymorphism reducing the risk of acquiring HIV-1 infection 
and the rate of disease progression in infected adults (Kostrikis et al., 1999; Misrahi et al., 
1998). The effect of CCR5-∆32 gene on HIV transmission is dependent on the allelic 
composition of the gene. 
Similarly, the CCR2 V641 mutation, a conservative valine to isoleucine substitution in the 
transmembrane region, has been observed as having some protective effects against HIV 
infection and reduce progression of HIV to AIDS (Chakraborti & Banerjea, 2002).  The 
protective effect of CCR2 V641 is believed to involve cross regulation through linkage 
disequilibrium, particularly in the regulatory region or promoter region of CCR5. CCR2V64I 
is said to be more pronounced among Africans (Matte & Roger, 2001), yet this is the most 
affected race (UNAIDS, 2008c) by the HIV pandemic than the non-African race, making the 
protective abilities of this chemokine co-receptor questionable and controversial. 
1.2 Background 
In mid 1996, scientists made a breakthrough in the field of HIV research when they 
discovered that chemokine co-receptors were crucial in the transmission of HIV-1 infection 
(Cohn & Weaver, 2006). That finding boosted the prospects of finding a therapy for HIV 
infection. Later on this finding was followed by yet another interesting discovery that some 
people remained uninfected by HIV-1, despite multiple unprotected sexual exposures while 
others when infected with HIV-1 remained asymptomatic for a long time and these people 
were deemed as long-term non-progressors (Rowland-Jones, 1998). Both developments were 
attributed to the role of chemokine co-receptors in HIV infection (Kostrikis et al., 1999; 
Misrahi et al., 1998; Rowland-Jones, 1998). 
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 Before the discovery of chemokines co-receptors, only the role of the CD4 molecule as a 
high-affinity receptor for HIV was known; but it was later on discovered that the CD4 
molecule receptor was not sufficient for HIV infection to occur (Stephens, Claiborne, Reich, 
David, Goldstein & David, 1998). It was in 1996 that the identity and contribution of other 
co-receptors in HIV infection and disease pathogenesis were recognized (Stephens et al., 
1998).  
Chemokine receptors are inherited host genetic factors that are known to determine the 
structural, physiological and biochemical characteristics of a host’s cell. This inherited 
information can be passed on from one generation to the other (Tylor, Green & Stout, 1997). 
In certain circumstances, chemokines receptor genes undergo natural mutations or mutate 
under the influence of mutagens.  
Factors leading to the concurrence of particular mutations include selective pressure, and 
historical events such as disease epidemics. While the cause of increasing HIV prevalence 
rates in parts of Asian and African continents may be attributed to social and demographic 
factors, as well as differences in the phenotype of the circulating viruses (Soto-Ramirez, 
Benjito, MacLane, Marlink, O’ Hara & Suttent, 1996), the racial distribution of risk factors to 
HIV infections has not been adequately explained. This raises the possibility that differences 
in the distribution of host genetic factors might influence the rate of transmission or the speed 
at which the epidemic is spreading in different racial groups. Infectious diseases such as the 
bubonic plague, small pox and pathogens including Yersinia pestis (an enteric pathogen) have 
been postulated to have generated a 32 base deletion in the CCR5 gene to CCR5-∆32 that is 
believed to account for the variations in prevalence of particular mutations within specific 
populations (Lalani, Masters, Zeng, Barret, Pannu, Everette et al., 1999; Libert, Cochaux, 
Beckman, Samson, Aksenova, Cao et al., 1998). Therefore, differences in prevalence of 
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certain mutations are increasingly pointing to differences in genetic polymorphism as an 
important factor that may be responsible for the distribution pattern and spread of HIV in the 
world (Michael, Nelson,   KewalRamani, Chang, O’Brien, Mascola et al., 1998). Despite that 
observation, prevalence rate and role of these factors in HIV transmission in high HIV 
endemic areas like Zimbabwe are not well described. 
1.3 Problem statement  
Although there are indications that CCR5-∆32 and CCR2V641 host genes confer some 
protection against HIV infection (Kostrikis et al., 1999; Misrahi et al., 1998; Christine, 
Hogan, Scott & Hammer, 2001; Anzala, Ball, Rostron, O’Brien, Plummer &  Rowland-Jones, 
1998), in Zimbabwe the role of these chemokine receptors in the transmission of HIV is not 
well described  (Williamson, Loubser, Brice, Joubert, Smith, Thomson et al., 2000). Yet the 
country is rated among the top five countries hardest hit by the pandemic in the world. It is 
therefore of great significance to understand the host genetic factors that are involved in the 
transmission of HIV, so that appropriate intervention programs can be put in place. 
1.4 Purpose of the study 
The proposed study intends to produce information on the key host genes that are associated 
with HIV transmission in the African population of pregnant women in Harare. Furthermore 
the information that is going to be produced might  contribute to the understanding of the role 
of  CCR5-∆32  and  CCR2V641 host genes, in the dynamics, evolution of the epidemic, and 
in designing effective chemotherapeutic drugs and vaccines directed against the chemokine 
co-receptor sites.  
1.5 Outline of the thesis 
This thesis describes how the prevalence of CCR5-∆32 and CCR2V641 genes were 
determined and compared in HIV infected and uninfected population of pregnant women 
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from Harare in Zimbabwe. Chapter 2 reviews the literature on the current global, regional and 
the Zimbabwean HIV situation. It   explains how CCR5-∆32 and CCR2V641 genes could 
have influenced this. The literature review chapter further  deal with  the global distribution 
of CCR5-∆32 and  CCR2V641 genes, and on  how the discovery of these chemokine  co-
receptors have contributed   in the designing of effective HIV-1 chemotherapeutic drugs and 
vaccines directed against the chemokine co-receptor sites. 
 Chapter 3 describes different methods that were systematically employed in order to achieve 
the aim of the study. This chapter will be then followed by Chapter 4 which tells us about the 
findings (results) of this study. Chapter 5 which is the discussion section describes the results 
of the study and relates them to other studies elsewhere.  Chapter 6 then highlights the 
conclusion that was drawn from the study. Meanwhile the last chapter which is Chapter 7 
outlines the recommendations that were prompted by the study findings. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Outline of the literature review 
The role of host genes in HIV transmission has attracted a lot of scientific interest and as a 
result a lot of literature is currently being generated. The current study investigates the 
frequency and role of host genes in HIV infection in Zimbabwe among pregnant women. The 
literature herein describes the global epidemiology of HIV, global distribution of host genes 
and how these host genes may have influenced the global distribution and transmission of 
HIV infection. The literature also explains how the discovery of these chemokines co-
receptors have contributed   to the designing and development of HIV-1 chemotherapeutic 
drugs and vaccines directed against the chemokine co-receptor sites. 
2.2 Epidemiology of HIV 
The global distribution of the HIV infection has been very interesting.  The first major 
epidemics of HIV were described in countries of central and eastern Africa, but today the 
epidemic is now far worse in the southern part of the continent, the Sub Sahara Africa (SSA).  
SSA is only home to 10% of the world’s population, yet today more than 70% (22.5 million) 
of people with HIV infection in the world is currently found in this region (UNAIDS, 2007) 
as shown in Figure 1.  
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Total: 33.2 million 
Source: UNAIDS, 2008b 
Figure 1 : Global estimates of HIV infected adults and children as end of 2007. 
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This global picture is said to be the result of distinct epidemiological profile resulting from a 
variety of contributing factors displaying large heterogeneity in different regions. These 
factors include: frequency of sexual contact, number and risk characteristics of sexual 
partners, concurrent partners, condom usage, circumcision, alcohol and/or drug use, stage of 
the epidemic and likelihood of encountering infectious individuals, background 
immunological status, pressure from co-infections, access to relevant health care and host 
genetic factors (UNAIDS, 2007; Libert et al., 1998).  
 
A number of things have also happened in the epidemiology of HIV since the discovery of 
the interplay between host and viral factors. A breakthrough in the understanding of host 
factors (chemokine co-receptors) that affect disease progression and susceptibility to HIV 
infection occurred in 1996, when it was observed that chemokine co-receptors were 
necessary for HIV entry into CD4 cells (Christine et al., 2001). This discovery was followed 
by a decline in HIV prevalence globally, regionally and Zimbabwe was no exception. For 
instance the global annual number of new HIV infections declined from 3.0 million in 2001 
to 2.7 million in 2007 (UNAIDS, 2008b). In SSA most countries recorded a decline in HIV 
infection among the pregnant women aged between 15-49 years between 2002 and 2006 
(UNAIDS, 2008c). In Zimbabwe HIV prevalence in pregnant women declined from 28% to 
16 % between 2002 to 2006 (UNAIDS, 2008a). These changes in HIV prevalence also 
resulted in the drop in Zimbabwe’s annual HIV death rates between 2004 and 2007 as shown 
in Figure 2.  
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Source: UNAIDS, 2008a 
Figure 2: The annual number of deaths in Zimbabwe due to AIDS between 1990 and 2007 
 
This decline in HIV death rate between 2004 and 2007 (Figure 2) has been mainly attributed 
to sexual behaviour change and condom use (UNAIDS, 2005; UNAIDS, 2008a), and very 
little credit has been given to the influence of host genetic factors in HIV-1 infection. Yet the 
host genetic factors seem to play a crucial role in HIV infection and disease progression, in 
turn affecting the global trend and distribution of HIV infection.   
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2.3 HIV infection and progression to AIDS 
Entry into target cells by HIV occurs by a multi-step process that culminates with the fusion 
of viral and cellular membrane (Figure 3). To enter the target cells, HIV interacts with CD4 
receptor via its gp120 protein, thereby stimulating a conformational change in gp120, which 
exposes a portion of transmembrane glycoprotein gp41, and allows access of the gp120 V-
loop to either CCR5 or CXCR4. Subsequently, a peptide in gp41 causes the fusion of the 
viral capsid to enter the target cell.   (Buseyne, Janvier, Teglas, Ivanoff,  Burgard & Bui, 
1998; Pierson & Doms,  2003) (Figure 3). HIV-1 infection depends on the chemokine 
receptors and co-receptors for attachment to the hosts’ cells. Polymorphisms in these human 
chemokine receptor systems will therefore affect the evolution of HIV-1 (Kaslow & 
McNicholl, 1999). 
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(Figure adapted from Michael Zaiac, New Product Development, 2005) 
 
Figure 3: CCR5 co-receptor conformational changes exposes the co-receptor binding site in 
gp120. HIV-1 enters the target cells after interacting with CD4 receptor via its gp120 protein. 
 
2.3.1 Stages in HIV infection 
Following infection (Figure 4), an acute disease syndrome may occur within two to five 
weeks characterised by general lymphopeneia and high-level viremia. Clinical manifestations 
of primary stage are characterised by general malaise, headache, myalgia, arthralgia, diarrhea 
and lymphadenopathy (Perelson, Essenger & Ho, 1997; Fauci, 1998). An acute immune 
response involving viral neutralising antibodies and cytolytic T-cells reduces the initial 
varemia substantially, and a baseline level of viral replication is established and this is 
referred to as the viral set-point. HIV result in the progressive depletion of cells of the 
immune system: CD4 T-lymphocytes, macrophages, monocytes, and dendritic cells. T-cell 
CCR5 
gp 41 gp 120 
CD4 
HIV-1 
T-Cell Surface 
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depletion may be as a result of direct killing of mature T-cells with the rapid replication of 
HIV-1 (Perelson, Essunger & Ho, 1997). Alternatively CD4 cells may be lost by activation 
induced death, innocent by-stander effect or by lack of proper cytokine stimulation (Clark, de 
Boer, Wolthers & Miedema, 1999; Ho, Neumann, Perelson, Chen, Leonard & Markowitz, 
1995). The amount of virus in the blood appears to be well correlated with disease 
development and progression. Eventually, the weakened immune system becomes unable to 
control a range of endogenous and environmental pathogens, leading to clinical illness and, 
ultimately death in most individuals (Fauci, 1998; Kahn & Walker, 1998). However, certain 
precipitating factors can either hurry or delay the disease progression process. These 
comprise of host genetic factors like CCR5-∆32 and CCR2V64I mutations that have been 
observed to delay progression of HIV infection to AIDS or death (Christine, Hogan, Scott, 
Hammer, 2001) among others. 
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Figure 4: Natural history and progression pattern of HIV infection to AIDS in the absence of 
treatment (Figure taken from Fauci, 1998). 
 
2.4 HIV and Host genetic factors 
Host genetic factors, including chemokine receptors and chemokine genotypes, have been 
identified as having an impact on both HIV-1 infection and disease progression to death 
(Michael, 1999). These findings prompted more research work that discovered two sets of 
factors (virus related and host immunologic factors) that have profound effect on HIV-1 
transmission and disease progression. The relationships between the two sets of factors have 
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provided valuable tools in monitoring ARV therapy (Kumud  Barroga, Hughes, Chen  
Raskino, McKinney, 2003). Polymorphisms within coding and regulatory regions of 
chemokine receptors and co-receptors have an impact on HIV-1 related pathogenesis. The 
presence of CCR5- ∆32, deletion of 32 base pairs from the coding region of CCR5 gene, 
leads to the encoding of a distorted CCR5 protein. This has been reported to provide partial 
protection against HIV-1 infection in people who are homozygous for mutant genotypes 
(Dean, Carrington, Winkler, Huttley, Smith, Allikmets, 1996; Liu, Paxton, Choe,  Ceradini, 
Martin, Horik,1996). Heterozygotes for a ∆32 deletion (CCR5-wt/∆32) are not protected 
against HIV-1 infection but manifest slow progression to HIV-1 and AIDS end points 
(Shearer, Kalish & Zimmerman, 1998; Kostrikis et al., 1999).  
 
On the other hand, A G to A substitution at position 180 affects the gene that codes for CCR2, 
a minor HIV-1 co-receptor. This mutation causes substitution of Isoleucine to Valine at 
position 64 (designated as CCR2V64I) which eventually slows down disease progression in 
adults (Smith, Dean, Carrington,Winkler, Huttley, Lomb et al., , 1997; Kostrikis et al., 1999). 
Similarly mutations in the 153’untranslated region of the gene that codes for SDF-1β (pre-B 
growth stimulating factor) lowers progression of HIV-1 infection to AIDS because SDF-1 is 
a natural ligand for CXCR4 which acts as a co-receptor for HIV-1 (Winkler, Modi, Smith, 
Nelson, Wu & Carrington, 1998; Yuan, Peterson, Wang, Goodsaid & Waters, 2000). Thus 
generally chemokines co-receptors seem to have some varied influence on the transmission of 
the AIDS causing virus. 
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2.5 CCR5 ∆ 32 and CCR2 V64I  
2.5.1 Trends of CCR5 ∆32 and CCR2 V64I in populations 
The global distribution of chemokine co-rereceptors genes among different populations has 
been heterogeneous, just like the distribution of the HIV infection. This scenario has led to 
the suggestion that there might be some underlying factors influencing  susceptibility to the 
virus in some populations compared to others (Martinsoni et al., 1997), since genetic 
mutation in host genes has been reported to show some strong geographical traits (Novembre, 
Galvani, Slatkin, 2005; Schliekelman, Garner, Slatkin, 2001). 
 
A general North to South downhill gradient in CCR5-∆32 has been observed as shown in 
Figure 5, with only the Lapps (Saamis) constituting a notable exception. The highest 
frequency has been found in Northern and North Eastern Europe (16% in Finnish and 
Mordvinian populations). The Swedish Saamis have been reported as having a significantly 
lower frequency (8.3%) of CCR5 -∆ 32 gene than Swedes.  The highest of the frequencies 
has been observed in northern Europe and the lowest in Greece (Libert et al., 1998). This data 
confirm the high frequency of CCR5-∆ 32 among northern European Caucasians, a gene 
frequency cline across Europe and Asia reflecting recent population admixture, and virtual 
absence of CCR5-∆ 32 among native Africans, East Asians, and American Indians (Stephens 
et al., 1998). Based on the demographic distribution, it is believed that the mutation arose in 
northern Europe in response to selective pressures due factors such as infection epidemics 
(Libert et al., 1998). 
 
Previous studies have suggested that the CCR5-∆32 gene was absent among Africans, 
American-Indiands and East Asians. Subsequent research has largely sustained these 
geographical patterns, although geneticists have observed that the allele was not wholly 
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absent from non-Eurasian populations, but is also detected in people of African descent 
(Novembre et al., 2005; Schiekelman et al., 2001). In Africa, a South African study 
conducted by Williamson and colleagues (2000) indicates that the allelic frequency of CCR5-
∆32 mutation was 0.1% in the black South African population, suggesting that the 32 base 
pair gene mutation could be drifting from the north to the south due to population admixture.   
 
 
 
Source: Libert et al., 1998. 
Figure 5: Frequency of the CCR5-∆ 32 allele in European populations. Schematic map of 
Europe indicating the frequency (in percentage) of the CCR5 mutant allele CCR5-∆32 in the 
various populations. 
 
On the other hand the frequency of CCR2V64I allele has been observed to be higher than that 
of CCR5-∆32 with a prevalence rate ranging from 10% to 25% in both black and white 
persons and in all other ethnic groups studied (Christine et al., 2001). Studies investigating 
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the distribution of the CCR2V64I mutation and allelic frequencies in different populations 
and ethnic groups worldwide ( Martinsoni et al., 2000; Struyf , Thoelen, Charlier, Keyaerts , 
Van der Donck, Wuu, 2000; Mangano, Kopka, Batalla, Bologna, Sen  & Barbouche, 1998; 
Iyer, Kim, Bando,  Lu, Gregg & Grody, 2001)  indicate that this mutation is most common in 
Asian populations (0.250), least common in Europeans (0.098), and of intermediate 
frequency (0.151) in African populations (Smith et al., 1997).  In Africa, studies carried out 
suggest that CCR2V641 vary among ethnic groups with a frequency of 13% particularly in 
South Africans, while another study showed a 23% frequency in Kenyans (Martinson et al., 
1997; Smith et al., 1997).  Further to that, Anzala and co-workers (2000) observed that the 
presence of the mutation helped to delay HIV-1 progression to AIDS among 21% to 46% of 
slow progressors in their study among infected commercial sex workers in Nairobi, Kenya. 
2.5.2 Chemokine coreceptor Polymorphism and HIV-1 Infection 
2.5.2.1 CCR5-∆32 polymorphism and HIV infection 
The macrophage-tropic HIV-1 uses the CCR5 to infect macrophages. The chemokine co-
receptors 5 (CCR5) gene has been identified as the main co-receptors that, in conjunction 
with CD4, aids the viral fusion and infection of human host cells by macro-phagic-tropic 
human immunodeficiency virus type 1 (HIV-1) strains (Deng, Liu, Ellmeier, Choe, Unutmaz, 
Burhart & Di Marzio, 1996; Dragic, Litwin, Allaway, Martin, Huang & Nagashima, 1996). 
Over the past few years, a number of mutations in CCR5 have been identified as natural 
genetic polymorphism able to influence the probability of acquiring HIV-1 infection or to 
affect the rate of disease progression, in infected adults (Kostrikis et al., 1999) or infants 
(Misrahi et al., 1998), though the allelic composition of the gene plays a crucial role in 
determining the outcome of exposure. Numerous studies now support the hypothesis that the 
homozygosis for a 32 base pair deletion (∆32) within the CCR5 gene is associated with 
complete resistance to HIV-1 infection (Liu et al., 1996). Liu and co-workers, (1996) 
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observed that individuals homozygous to CCR5-∆32 gene remained uninfected with HIV-1 
despite multiple exposures to the virus. Further to that, Michael and collaborators (2001) 
demonstrated that CCR5-∆32 homozygous gene was associated with protection against HIV 
infection in a cross-sectional and longitudinal analysis of a cohort of 2996 of initially HIV 
sero-negative individuals comprising of homosexual men, male and female injection drug 
users (UDIs) and heterosexual risky women in North America. 
2.5.2.2 CCR2V64I polymorphism and HIV infection 
During the last five years, several communications have been published about the 
discovery of hereditary alterations of human genome determining resistance to HIV-1 
and/or the rate of disease progression. The genome changes have been associated with 
the genes encoding chemokines or their receptors, which are secondary HIV-1 attachment 
sites to the immune cells. The changes include a point mutation at position 64 of the 
CCR2 receptor gene (causing Valine to substitute Isoleucine on the receptor protein). 
 
 The protective effect of CCR2 V641 against HIV infection has been controversial. A number 
of studies have observed that adults who possess the CCR264I allele (isoleucine substitution 
for valine at position 64) are not protected against HIV-1 infection, but progress less rapidly 
to disease once infected (Christine et al., 2001). Others suggest that CCR2V64I interferes 
with CCR5 co-receptors expression; however this hypothesis was rejected by a recent in vitro 
study showing that the CCR2V64I allele does not influence CCR5 transcription or mRNA 
levels (Matte & Roger, 2001). Contrary to that, a study of infected commercial sex workers in 
Nairobi, Kenya, suggests that the presence of the mutation helped to delay progression of 
HIV-1 infection to AIDS in 21% to 46% of slow progressors (Anzala, Ball, Rostron, O’Brien, 
Plummer, & Rowland-Jones, 1998). 
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2.5.3 Chemokine receptors in HIV-1 therapeutic development 
Targeting of viral co-receptors to block HIV entry has been a promising approach to prevent 
and treat HIV-1 infection. The human immunodeficiency virus 1 (HIV-1) enters CD4 + cells 
by fusion at the plasma membrane after interactions with CD4 and co-receptor molecules 
(Berger, 1997). The first co-receptor to be identified was CXC chemokine receptor CXCR4 
(Feng, 1996), closely followed by the CC chemokine receptor CCR5 (Alkhatib, Combadiere, 
Broder, Feng, Kennedy, Murphy, 1996). These two proteins are generally considered to be 
the most important co-receptors used by HIV-1 strains of the T-tropic and M-tropic 
phenotypes, respectively (Berger, 1997). 
 
Nature has provided a model for blocking CCR5, that is, people who express a deletion 
mutation of CCR5 (CCR5-∆32) on their cell surfaces. The protective property of CCR5-∆32 
against HIV infection has prompted pharmaceutical companies to develop a CCR5 antagonist 
for clinical use (Clotet, 2007). One such CCR5 antagonist that has been developed recently is 
Maraviroc.  
 
Maraviroc is a CCR5 antagonist that selectively binds to the human chemokine receptor 
CCR5, present on the cell membrane, preventing the interaction of HIV-1 gp 120 and CCR5 
necessary for CCR5-tropic HIV-1 to enter cells. The drug has shown potent activity against 
multidrug-resistance CCR5-tropic HIV-1 strains. It has antiviral activity in vitro against 
CCR5 tropic HIV-1, including 43 HIV-1 isolates from various clades and geographic regions, 
as well as 200 HIV-1 envelope-derived pseudoviruses. Maraviroc has no activity against 
CXCR4-tropic and dual tropic HIV-1 (Sayana & Khanlou, 2008). Data gathered from human 
drug trials with Maraviroc demonstrates that it is efficient and safe to use in combination with 
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other antiretroviral agents for treatment-experienced adults infected with only CCR5 tropic 
HIV-1, who have evidence of viral replication (Sayana & Khanlou, 2008).  
 
Despite the availability of  evidence linking some host genetic factors to protection against 
HIV infection, very little information is still available on the role of CCR5-∆32 and 
CCR2V64I polymorphism on HIV transmission in Africa’s high endemic areas (Williamson 
et al 2000), like Zimbabwe. Yet the current HIV situation suggest that the very future of 
Africa is threatened (Kaul, Makadzange & Rowland-Jones, 2000) and perinatal HIV-1 
infection constitutes a significant global health problem and the prevention of transmission 
has to be a high public health priority. Therefore, knowing the range of co-receptors that 
could be used by HIV-1 in invivo is important for the development of antiviral drugs aimed at 
inhibiting HIV-1 entry.  
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CHAPTER 3: METHODOLOGY 
 
3.1 Aim 
The aim of the study was to determine and compare the prevalence of homozygous 
CCR2V641 and homozygous CCR5-∆32 mutations in a HIV positive and HIV negative 
population of pregnant women from Harare, in Zimbabwe. 
3.1.1 Objectives 
The objectives of the study were: 
• To determine and compare the prevalence of homozygous CCR5- ∆32 mutation in a 
cohort of HIV positive and HIV negative population of pregnant women from Harare in 
Zimbabwe. 
• To determine and compare the prevalence of homozygous CCR2V641 mutation in a 
cohort of HIV positive and HIV negative population of pregnant women from Harare in 
Zimbabwe.  
• To assess   if there is any association between   homozygous CCR2V641 and 
homozygous CCR5 -∆32 mutations with HIV infection in a cohort of HIV positive and 
HIV negative population of pregnant women from Harare in Zimbabwe.  
• To assess if sexual transmitted infections had any influence on the outcome of the current 
study.  
3.2 Study design 
This was a cross-sectional study of homozygous CCR2V641 and homozygous CCR5 -∆32 
mutations in which measurement of exposure (chemokine co-receptor status) and effect 
(HIV-status) were made at the same time. The current study had to adopt this design because 
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it is relatively easy and economical to conduct and is useful in investigating exposures that 
are fixed characteristics like the chemokine co-receptor genes.  
3.3 Definition of terms 
CCR2V641- A substitution of valine for isoleucine in the CCR2 receptor gene, resulting in 
normal levels but altered first transmembrane region of the CCR2 receptor, which has been 
associated with delayed progression of HIV-related illness. 
CCR5∆-32- A 32 base deletion in the CCR5 gene that results in a shortened and non-
functional protein. Homozygosity for CCR5-∆32 is associated with decreased susceptibility 
to HIV, and heterozygosity is associated with delayed progression of HIV-related illness. 
CCR5-A chemokine receptor present on microphages, monocytes, and some T cells, 
particularly memory T cells. Along with CD4, CCR5 acts as a co-receptor for M-tropic HIV. 
CXCR4- Chemokine receptor located on T cells, particularly naive T cells, which, along with 
CD4, acts a co-receptor for T-tropic HIV. 
Chemokine co-receptor –These are molecules that are found on CD4 -T cell which in 
conjunction with CD4 molecules cell facilitate host cell entry by the HIV. 
Polymorphism- Different forms of a gene existing in different forms caused by gene 
mutation or deletions. 
Macrophage-tropic (M-tropic) – HIV variants with a non-syntium-inducing phenotype that 
infect monocyte –derived macrophages in vitro but not established CD4 + T-Cell lines. Also 
called R5 variants because they use the CCR5 co-receptor for entry, they tend to be the 
predominant variant during early infection. 
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T-cell-tropic HIV – HIV variants with a syncytium-inducing phenotype that infects 
established CD4 T-cell lines. Also called X4 variants because they use the CXCR4 co-
receptor for entry, they tend to emerge during a later stage of HIV infection.  
Host genetic factors- These are inherited genetic materials that lead to the encoding of 
proteins or amino acids that confer protection or pre-dispose one to HIV infection. 
Wild type gene- A gene without mutation either of a pair (or series) of alternative forms of a 
gene 
Allele- An allele is one of a pair of alternative forms on the DNA sequence of a particular 
gene . An allele can be RR (dominant), Rr (dominant), and dd (recessive). Alleles can be 
homozygous (same)-RR and rr or heterozygous (different)-Rr. 
Validity- Validity determines whether the research truly measures that which it was intended 
to measure or how truthful the research results are. 
Reliability- Is the extent to which the results of a study are consistent over time and is an 
accurate representation of the total population understudy. Results of a reliable study should 
be reproduced under a similar condition and methodology. 
Main study- An ongoing study from which the current study drew its samples from. 
STIs – These are sexual transmitted infections (genital, warts, genital ulcers, HVS-2, 
Trichomonas vaginalis and syphilis) 
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3.4 Study population 
 
This was a baseline survey of sera samples collected from pregnant women in three clinics 
namely Epworth, St Marys’ and Seke North in Harare. The 76 HIV positive sera samples 
were randomly drawn from 456 HIV infected pregnant women, while 166 HIV negative sera 
samples were randomly selected from 594 HIV uninfected pregnant women. The selection of 
samples was done using an existing sample register and 166 samples were supposed to be 
selected from each group. The number had been inflated in order to cater for attrition due to 
method failure. However, positive samples ended up being less than the negative samples 
because most of the samples were insufficient to conduct the assays.  
The serum samples had been drawn from pregnant women who had participated in the main 
study entitled “PREVENTION OF MOTHER TO CHILD TRANSMISSION OF 
SEXUALLY TRANSMITTED INFECTIONS” in peri-urban Harare between 2002 and 2004.   
3.4.1 Inclusion criteria 
The study population from where the sera samples were drawn from were pregnant women of 
any race residing in Zimbabwe   with a minimal age of 18 years using Epworth, St Mary’s 
and Seke North clinics for ANC.   These clinics have been selected    as sites for the main  
study because they have been reported to have   a higher prevalence of HIV infection in 
Harare. 
3.4.2 Exclusion criteria 
The main study excluded women who were not pregnant. As a result our sera samples were 
all from pregnant women. 
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3.5 Sampling  
3.5.1 Sample size calculation 
Sample size for this sub-study was determined using sample size calculation for single 
proportion.  The formula for the calculation is as given below. 
Sample size= zα2/∆2   x p (1-p)  
  Where   p     = 25 % and is the assumed prevalence of CCR2V641 gene polymorphism in 
Zimbabwe. This was based on the prevalence rates from the study by Matte et al., (2001) 
who observed that the prevalence of CCR2V641 ranged from 10-25% in both black and 
whites as the exactly prevalence of the gene is not known in Zimbabwe.  
∆
    
= The precision, in this case was set at 0.05 
Where zα  = 1.96  
 Sample size =288  
When the sample size was calculated using the lower limit prevalence rate of p=10% based 
again on Matte et al., (2001) study, a sample size of 138 was produced. It follows that the 
possible range of the acceptable sample size lied between 138-288 samples. 
3.5.2 Controlling for sampling bias 
242 samples were randomly selected from 1050 serum samples for this study. 76 HIV 
positive samples were randomly selected from 456 HIV positive serum samples, while 166 
HIV negative samples were randomly selected from 594 HIV negative serum samples, all 
available from the main study. All serum samples were collected from pregnant women who 
had visited the clinic to register as well as for routine antenatal clinic visits and later on 
volunteered to participate in the main study. It is therefore assumed that these 242 samples 
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represented the host genes to HIV infection of the 1050 samples from pregnant African 
women in peri-urban Harare.   
 
3.6 DATA COLLECTION 
3.6.1 Demographic data 
General demographic data consisting of age, race, and sexual transmitted disease status for 
mothers with randomly selected samples were drawn from the existing main study register. 
3.6.2 Blood samples 
Blood samples in the main study were collected as follows:  
-5ml  of blood was drawn from the venepuncture into an anticoagulant free sample 
tube for sera separation. 
3.6.3 Laboratory methods  
3.6.3.1 Sample collection and processing  
The serum samples that were used in this study were part of the 1050 samples collected from 
the parent study entitled “PREVENTION OF MOTHER TO CHILD TRANSMISSION OF 
SEXUALLY TRANSMITTED INFECTIONS”. In brief 5 ml of whole-blood was collected 
in an anticoagulant free VACUTAINER tubes for each person. The clotted whole-blood 
samples were centrifuged for 20 minutes at 1,200 g in a swinging bucket rotor (RT 6000B; 
Sorvall) centrifuge. Sera was then aliquoted into cryovials (Nalgene, Nunc International, 
Roskilde, Denmark) and stored at  -70 0 C in a deep freezer. After extraction the samples 
were then shipped on dry ice to the institute of Microbiology in Oslo in Norway for CCR5-
∆32 and CCR2V641 polymorphism determination.  
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  3.6.3.2 HIV testing 
HIV status of the samples was drawn from the main laboratory result register. These samples 
had been tested as follows:  
- Serial HIV-1/2 algorithm antibody tests were done using Determine (Abbot 
Diagnostics, Illinois, USA) and Ora-Quick (Abbot Diagnostics, Illinois, USA) rapids 
kits on mother sera samples in the main study.  
3.6.3.3 STIs screening 
Antibodies to HSV-2 at baseline were identified using the HerSelect 2 ELISA IgG(Focus 
Diagnostics) and the results were interpreted according to the manufacterers’specifications. 
Screening of syphilis was done using a non-specific rapid plasma reagain (RPR) and all 
positive were confirmed using Triponema Pallidium Hemaglutination Assay (TPHA), both 
manufactured by Randox Laboratories. A wet mount prepared from freshly collected vaginal 
fluid was mixed with normal saline and examined using a compound microscope for the 
presence of Trichomonas vaginalis and yeast cells. 
3.6.3.4 CCR5-∆32 and CCR2V641 polymorphism determination using PCR 
 
DNA was extracted from serum samples following the guadine isothiocyanate acidified silica 
procedure of Boom, Sol, Salisman, Jansen, Wertheim-van Dillen and van der Noorda (1990) 
(see Appendix  7 for procidure).  
3.6.3.5 PCR controls 
Interpretation of assay results was based on positive   controls that were simultenously tested  
together with the samples. In the current study, plasmids containing the gene of interest were 
used as controls for both the CCR5-∆32 and CCR2V64I PCR assays. The plasmids were 
obtained from Eurofins MWG Operon in German (see appendices 10, 11, 12 & 13)  
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The CCR5 wild type plasmids  had a 200 base pair (bp) insert of the CCR5-∆32 gene (see 
appendix 10). The  CCR5-∆32 gene  had a 32 base pair deletion, resulting in a 168 bp product 
(see  appendix 11).The CCR2 wild type and CCR2V64I plasmid contained  a 380 bp insert 
(see Appendix 12 & 13).  
 
 
 
 
 
Figure 6: A cabinet where the sample extraction was done from. Working under the cabinet 
was necessary to maintain aseptic conditions in order to avoid contamination of samples with 
foreign- DNA. 
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3.6.3.6 Agarose gel electrophoresis 
To assess whether the DNA was successfully extracted from the samples before testing for 
chemokine co-receptors, 10 % of the samples were amplified and PCR products were then  
loaded on 2 % agarose gel and electrophoresed. This was done by mixing 10 µL of DNA 
elute (about 5 µg) with 1 µL of 1X Loading Buffer (30% Glycerol, 0.25% Bromophenol 
Blue, 0.25% Xylene cyanol) and loaded onto 2.0 % (w/v) agaraose gel in 1X Tris-Borate 
EDTA (TBE) diluted appropriately from the TBE stock solution, 0.054g Tris-Base, pH 8, 
27.5g boric acid, 20 ml of 0.5 M EDTA, pH 8.0) (see Appendix 7). The gel was 
electropheresed for a run time of 1 hour at a constant power of 100 V using Bio-Rad 
PowerPac 1000 (Bio-Rad, Ivrysur-Seine, France).  
The genotyping and amplification of CCR5-∆32 and CCR2V641 polymorphism were 
performed using a simple and fast automated method based on real-time PCR on an Applied 
Biosystems Step One Plus Real-Time PCR system (Figure 7) (Applied Biosystems, Foster 
City, California, USA) and Light Cycler TM technology (Roche Diagnostic, Rahway, NJ, 
USA)  respectively. The method had two steps: (1) real-time PCR amplification and (2) 
melting curve determination. 
3.6.3.7 Real time PCR amplification 
During this process, amplification and fluorescent detection steps were done in the same tube 
and data recorded online.  The PCR instrument then measured the accumulation of PCR 
products during amplification with the fluorescent dyes. 
3.6.3.8 Principle of SYBR green technology and melting curve 
SYBR green binds to the double-stranded DNA, and upon excitation emits light which can be 
measured at a certain wavelength. Thus as the PCR product accumulates, fluorescents 
increases. However, when SYBR green double-stranded complex is heated, the double 
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stranded DNA dissociate at different rates, since the energy required to break the base-base 
hydrogen bonding between two strands of DNA is dependent on their length, GC and their 
complementarity. The dissociation of the DNA during heating is measured by the large 
reduction in fluorescence that results in SYBR enabled product on Applied Biosystem 
StepOneTM  Real time -PCR instrument.  Genotypes homozygous for the mutant allele have a 
low melting point than do geneotypes wild type for the mutant allele. 
3.6.3.9 Melting curve determination 
During the melting curve analysis with SYBR Green, products were characterised, in order to 
determine whether they had a deletion or not. PCR products were characterised by melting 
curve analysis because each double-stranded DNA molecule had a characteristic melting 
temperature (Tm), at which 50% of the DNA is double- stranded and 50% is melted, i.e, 
single-stranded. During a melting curve run, the reaction mixture was slowly heated to 950C, 
which caused dsDNA to melt. A sharp decrease in SYBR Green fluorescence occurs when 
the temperature reach the Tm of a PCR product present in the reaction. The Applied 
Biosystems Step OneTM Plus Real-time PCR machine continuously monitor fluorescence 
during temperature transitions. The computer software displayed these data as a melting 
curve graph (fluorescence [F] vs. Temperature [T] (Figure 8). 
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Figure 7: A Medical Research Technologist testing the genomic samples for CCR5-∆32 
mutation on Applied Biosystem StepOneTM  Real-time PCR instrument at Oslo University in 
Norway. 
In order to determine the possible appearance of CCR5-∆32 alleles, real time PCR was 
performed on Applied Biosystems Step One Plus Real-time PCR system using a double 
strand-specific dye SYBRGreen ® . Primers flanking the CCR5-∆32 mutation were D32-F2, 
5’TTCATTACACCTgCAgCTCTC3’ and D32-R, 5’gACCAg CCCCAAgATgACTATC-3’. 
(TIB MOLBIOL Syntheselabor GmbH, Germany) (see Appendix 3 for primer 
specifications). Each 20µl reaction mix contained 5µl of genomic DNA; 10 µl of 2x SYBR 
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Green mix (POWER SYBR®  GREEN PCR MASTER MIX); and 3 µl (10 pmol) of each 
primer (D32F2 and D32 R). Forty cycles of amplification were performed in three different 
stages consisting of various steps in an Applied Biosystems Step One Plus Real-time PCR 
machine as describe below:  
Stage 1: Activation of enzyme 
  Step 1: 950C for 10:0 minutes 
Stage 2: PCR x 40 
  Step1: 950C for 0:15s  
  Step 2: 600C for 1:00 minutes (min) 
Stage 3:  Melting curve  
  Step 1: 950C for 0:15s 
  Step 2: 600C for 1:00 min, then 0.30C/slope up to 950C  
  Step 3: 950C for 0:15s 
Fluorescence was measured at 520nm of the fluorometer.  Amplicons containing the 32 –bp 
deletion were supposed to have a melting temperature ( Tm  ) which was approximately 20C 
lower than that of the 83 bp (Figure 8) (Ruiz, 2001). Genotypes homozygous for the mutant 
allele had a low melting point than do geneotypes wild type for the mutant allele (72.2 versus 
74.280C). 
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Figure 8: Analysis of the flourescent measured during melting curve determination of CCR5 
in Applied Biosystems Step OneTM Plus Real-time machine. Genotypes homozygous for the 
mutant allele had a low melting  point than do genotypes wild type for the mutant allele (72.2 
versus 74.280C). 
 
For CCR2V64I genotyping, real-time PCR was performed in the LightCycle TM     system. 
The determination of CCR2V64I in a LightCycle TM     system was based on Fluoresence 
Resonance Energy Transfer (FRET).  
 
 
74.280 C  (Homozygous 
gene for CCR5 wild type) 
72.200 C 
(Homozygous 
gene for CCR5-
∆32) 
Melting point peaks 
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3.6.3.10 FRET Principle 
 
FRET analysis is based on the transfer of energy from one fluorescent molecule (e.g 
fluorescein) to another adjacent fluorescent molecule (e.g LightCycle rTM     system Red 640). 
In FRET, fluorescein is excited by blue light, leading to the emission of fluorescent light with 
a wavelength of 530 nm and transfers of this energy to LightCycler TM     640 molecule (which 
is not directly affected by the blue light). The LightCycler TM     640 molecule is in turn 
excited and emits light which is measured at 640 nm. 
Two different oligonucleotides (anchor and sensor) hybridize, head to tail, to adjacent regions 
of the target DNA, making possible the fluorescence resonance energy transfer (FRET) 
reaction. Due to the sequence specificity, artificial by-products such as primer-dimers or PCR 
by products are not detected.  
Flanking primers and internal probes were designed according to the sequences of interest 
(CCR2-F, ATgCTgTCCACATCTCgTTC-3´ and CCR2-R, 5´-
CCCAAAgACCCACTCATTTg-3´; CCR2Sensor-mt, 
5´AACATgCTggTCATCCTCATCTTAATAA-FL and CCR2 Anchor, LC640-
CTgCAAAAAgCTgAAgTgCTTgACTg-PH) (TIB MOLBIOL Syntheselabor GmbH, 
Germany) (see Appendices 4 & 5 for primer and probe specifications). Each 20 µl PCR 
contained 2 µl  of genomic DNA, 2 µl of Hyb Prob Enzyme-Master mix; 3 mM MgCl2     ; 2 
pmol of each Sensor  and Anchor  probes; and 10 pmol of each primer (CCR2-F and CCR2-
R). Denaturations were conducted for 2 minutes and were followed by 45 cycles of 
amplification (95 0C for 0s, 64 0C for 15s, 58 0C for 25s and 72 0C for 25s). Amplification 
was then followed by determination of the melting curve (950C for 20s, 640   C for 15 s, and 
580 C for 25s and from 45 0C to 950C, with a 0.20C/s slope), fluorescence was measured on 
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channels F2 (640 nm)/ F1 (520) of the fluorometer. During the temperature curve 
determination the melting point of the sensor was measured and depended on the 
presents/absence of mismatch along sequence (mutant vs wild-type allele). Amplicons 
containing the wild-type sequence was supposed to have an approximate melting point of 40C 
lower than amplicons with the polymorphism as shown below in Figure 9. 
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Blue vertical line- Melting point for CCR2wt/wt (wild type gene) 
Green vertical line- Melting point for CCR2-64I/64I (homozygous mutant gene) 
Figure 9: CCR2V64I analysis by Real time PCR. Analysis of the fluorescent measured 
during melting curve determination in the LightCycler system. Genotypes homozygous for 
the wild- type (wt) allele had a lower melting point than do genotype homozygous for mutant 
alleles (CCR2V64I/64I) (60.3oC vs 64.6oC ) 
 
3.7 Reliability 
Before the inception of the study the conductor and author of this study underwent training in 
the conducting of PCR technique in Norway for a month in 2009. A pilot study to test the 
data collection tools was done before the initiation of the laboratory tests. Constant 
CCR2 -64I/wt (heterozygous 
gene with two melting point 
peaks at 60.3oC  and  64.6oC) 
CCR2-64I/64I (melting 
point of 64.6oC) 
CCR2wt/wt gene( melting 
point of 60.3oC) 
Blue 
vertical 
line 
Green 
vertical line  
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supervision of the conductor’s laboratory work was done by an expert molecular biologist 
from Oslo University to ensure that data of highest quality was collected. 
Reliability was also ensured through the inclusion of positive and negative controls during 
testing in every test batch. These controls guided us on whether to accept or reject the assay 
results. Assays that were in disagreement with the controls were rejected and repeated.   
3.8 Validity 
The current study intended to investigate whether CCR5-∆32 and CCR2V641 chemokine co-
receptors were a risk factor for HIV infection. We adopted a number of factors to ensure 
validity. Firstly we used the real-time PCR technique to determine the chemokine co-receptor 
genes in sera samples instead of the conventional PCR end-point method. This technique has 
a number of advantages over other PCR methods, like the end-point method e.g  the 
technique is much faster. In addition to that real-time PCR produces reliable results, it is far 
more sensitive than  ethidium  bromide staining detection. Finally real-time PCR minimises 
the chance of contamination because both amplification and detection are conducted in a 
single closed tube (Leindios, Tyagi, Mhlanga, Ho, Kramer, 1998). 
3.9 Accounting for bias and confounding factors 
3.9.1 Information bias 
Although a questionnaire was administered to the participants to capture information on 
whether participants were suffering or had ever suffered from sexual transmitted diseases, the 
study could not rely on that information only, and thus samples were further examined by 
additional laboratory tests. 
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 3.9.2 Confounding  
To account for possible influence of confounders like STIs (sexual transmitted infections), 
multivariate regression analysis was used in the analysis of data. However, there may be 
other confounders like the nutritional status, number of sexual partners among others that 
could not be accounted for in this study. 
3.10 DATA   ANALYSIS 
Data was entered and analysed using SPSS program. Baseline descriptions of demographic 
characteristics were compared between mothers that had CCR5-∆32 and CCR2V641 
chemokine co-receptors and those who did not. Chi-square ( ᵪ2 )  tests and relative risks for 
CCR5-∆32 and CCR2V641 chemokine co-receptors were calculated. Thereafter, factors that 
had a p-value of less than 0.25 in the univariate analysis were included in multivariate 
regression analysis to control for their confounding effect. 
3.11 Ethical considerations 
This study was approved by the Medical Research Council of Zimbabwe (MRCZ) (Ref 
MRCZ/A1407).  Host genetic factors to HIV study is part of the HIV-1 Genetic diversity 
study and both are sub-studies of the main study entitled “PREVENTION OF MOTHER 
TO CHILD TRANSMISSION OF SEXUALLY TRANSMITTED INFECTIONS”. 
Participation in the main study and the Host gene study was absolutely voluntary.  
Prior to enrolment, the entire consent form (Appendices 1 & 2) was read to the participants 
either in Shona or English languages as the case may be.  Refusing to have any of one’s 
sample stored other than being used to complete the main study did not prejudice the 
participants’ involvement in any other future studies by us.  
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CHAPTER 4: RESULTS 
4.1 Demographic data  
Chemokine co-receptors results of CCR5-∆32 and CCR2V64I genes were available from 242 
Black African pregnant women (mean age 25.0 and 95% CI =24. 3-25.6 years). HIV infected 
mothers were significantly older (mean age 26.7, 95% CI = 25.6-27.7 versus mean age 24.1, 
95% CI =23.3-24.9, p<0.001) than HIV negative.  
4.2 Confirmation of DNA extraction from serum samples 
 
90% of the serum samples that were amplified and PCR products gel electrophoresed 
produced bands similar to those shown in Figure 10 below. 
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1                             2       3         4 
             
 
Figure 10: Electrophoresis in a 2% agarose gel of the amplicons resulting from real-time 
PCR. Lane 1 and 2 represents marker V (Roche ), lanes 3 and 4 show DNA bands for 
samples from participants. 
4.3 Prevalence of chemokines co-receptors and STIs 
None of the women had a CCR5-∆32 homozygous gene (Table 1).  76 of the 242 sera 
samples were drawn from HIV positive mothers, while the remainder was collected from 
HIV negative mothers. The overall prevalence of CCR2V64I homozygous gene was 24.4 % 
(n=59, 95% CI =18.93-29.83). Of the 59 individuals with CCR2V64I homozygous gene, 
49.15% (n=29) were HIV positive while the remainder was HIV negative. Results for 
heterozygous genes for both CCR5-∆32 and CCR2V64 genes could not be analysed because 
we had no controls for heterozygous genes to authenticate our laboratory results.  
 
Ladder  Results for gel electrophoresis of the real-time PCR products 
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Table 1: Genotype and allelic frequencies of CCR2 and CCR5 genes within pregnant 
women. 
 
Variable wt/wta wt/mtb mt/mtc Mutated allele 
frequency (%) 
 CCR2 183 ND 59 24.38% 
 
CCR5 242  ND 0 0% 
 
aWild type homozygous  (CCR5wt/ wt or CCR2wt/wt) 
bHeterozygous (CCR5∆32/ wt or CCR2V64I/64V) 
cMutant type homozygous (CCR5-∆32/ ∆-32 or CCR2V64I/64I) 
ND- Not determined 
 
On the other hand STIs like HSV-2 had the highest prevalence (51.5 %) (95% CI= 44.55-
58.39), while syphilis had the lowest prevalence (0.5 %, 95% CI=0.5-1.5) as shown in 
table 2. 
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Table 2: Prevalence of STIs among the study population. 
 
Variable Number  
 (n) 
Prevalence (%) 95% Confidence Interval (95% CI) 
Lower limit                   Upper limit 
HSV-2 204 51.5 44.55                  -                    58.39 
Candida albicans 218 34.86 28.49                  -                    41.24 
Bacterial vaginosis 170 24.12 17.62                  -                    30.61 
Trichomonas vaginalis 218 11.47 7.20                    -                    15.73 
Genital warts 206 5.8 2.6                      -                     9.1 
Genital ulcers 201 2.5 0.3                      -                      4.7 
Syphilis  193 0.5 0.5                      -                      1.5 
 
4.4 Factors associated with HIV infection 
In univariate analysis, mothers with CCR2V64I gene were two times more likely to contract 
HIV infection (RR=1.913, CI= 1.338-2.737, p=0.001) compared to those without the gene.  
All STIs (genital ulcers, HSV-2, Trichomonas vaginalis and syphilis) with the exception of 
genital warts were risk factors for HIV infection as illustrated in Table 3 below. 
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Table 3: Univariate analysis factors associated with HIV positivity among pregnant women. 
 
 
 
Variable 
 
 HIV positive  
Yes            No 
 
Relative Risk (RR) unadjusted (95% CI) 
 
 
p-value 
Total 
 
 
 76 
 
166 
 
 
 
 
 
CCR2V64I Yes 29 30 1 
 
 
 No 47 136 
 
1.91 (1.33-2.73) 0.001 
 
 
Genital ulcers* Yes 4 1 1  
 No 52 144 3.02 (1.83-4.95) 0.008 
 
Genital warts* Yes 4 8 1  
 No 53 141 1.22 (0.53-2.81) 
 
0.651 
 
 
HSV-2* Yes 52 53 1 
 
 
 No 5 94 9.81 (4.09-23.54) <0.001 
 
Trichomonas 
vaginalis* 
Yes 13 12 1  
 No 41 152 2.45  (1.54-3.89) 0.001 
 
Syphilis* Yes 1 0 1  
 
 
 
No 
 
41 
 
151 
 
4.68 (3.57-6.14) 
 
0.057 
 
 
 
 
 
 
*Denominator less than 242 
 
Further to that age was not associated with HIV infection in this study (RR=1, CI=1.00-
1.10) 
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To account for the confounding effects of other factors like STIs, further analysis were 
conducted using the multivariate regression analysis (Table 4) on variables that had 
shown a p-value of less than 0.25 in univariate analysis. In multivariate regression 
analysis participants with CCR2V64I gene were still two times (RR= 2.321, 95% 
CI=1.376-3.916) more likely to contract HIV infection than those without the gene. Other 
STIs were still associated with HIV infection.  
Table 4: Multivariate analysis of factors associated with HIV positivity among pregnant 
women using logistic regression analysis. 
 
 
 
Variable 
 HIV positive Relative Risk (RR) adjusted (95% CI) 
 
p-value 
 
 Yes No   
Total  76 
 
 
166   
CCR2V64I Yes 29 30 1 
 
 
 No 47 136 
 
2.32 (1.38-3.92) 0.002 
 
 
Genital 
ulcers* 
Yes 4 1                        1  
 No 52 144 2.20 (1.44-3.38) <0.001 
HSV-2* Yes 52 53                                             1 
 
 
 No 5 94 8.66 (2.66-28.21) <0.001 
 
Trichomonas 
vaginalis* 
Yes 13 12 1  
 No 41 152 1.71 (1.06-2.76) 0.027 
 
Syphilis* Yes 1 0 1  
 
 
 
No 41 151 3.56 (1.69-7.53) 0.001 
 
 
 
*Denominator less than 242 
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CHAPTER 5: DISCUSSION 
 5.1 Major findings of study 
The major findings of this study were that homozygous CCR2V64 gene and STIs were more 
prevalent in HIV infected pregnant women than in those who were not infected.  This study 
also demonstrated that homozygous CCR5-∆32 gene was absent from these pregnant women 
from Harare. 
5.2 Frequency of chemokines co-receptors 
5.2.1 CCR2 V64I gene  
The frequency of 24.38% in homozygous CCR2V64I gene in this study confirms what 
previous studies have reported that the gene had a frequency of 10% to 25% in all people 
studied (both blacks and whites) (Christine et al., 2001).  This study is also in agreement with 
studies carried out in Kenya that show a CCR2V64I gene frequency of 23% among the 
Kenyans (Martinson et al., 1997). Similarly, Anzala and co-workers, (1998) conducted  a 
study on infected commercial sex workers in Nairobi, Kenya, and observed that the presence 
of the mutation could help to explain the slow progression in 21% to 46% of the slow 
progressors. On the other hand, in South Africa, the frequency of CCR2V64I gene was 
almost two times less (13%) than in the current study (Smith et al., 1997) among South 
Africans. 
5.2.2 CCR5∆32 gene 
In contrast to CCR264I gene, no homozygous CCR5-∆ 32 allele was detected in any of the 
samples that were studied from Harare. The results augur well with other studies that have 
been conducted worldwide on CCR5-∆ 32 being absent in homogenous black populations, 
except in cases where there has been a gene flow from the Caucasian (white) to black 
population (Stephens et al., 1998).  
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Elsewhere, other studies have recorded a negligible prevalence of CCR5-∆32 gene in some 
African populations. A study done on African-Americans in US among people of mixed HIV 
infections showed a CCR5-∆32 allele frequency of 0.017 (Dean et al., 1996). While Liu and 
co-workers (1996) showed a prevalence of 0.2% for the CCR5 mutation in black Americans 
from their study in the USA.  
In Africa the CCR5-∆32 gene frequency has been less than 1%. For instance in South Africa, 
a study carried out by Williamson and colleagues (2000) showed the allelic frequency of the 
CCR5∆32 mutation of about 0.1% in the black South African population (n=1247). In 
agreement with this study, a Cameroonean study (Torimino, Wolfe, Thomas, Martin, 
Mpoudi-Ngole, Tamoufe et al., 2007) shows   no CCR5-∆32 mutants    in a population of 
1390 rural inhabitants. Similarly a study done on West and Central Africans also demonstrate 
an absence of CCR5-∆32 gene in this population (Samson, Libert & Doranz, 1996).  
Thus all studies point out to the absence or negligible frequency of the CCR5-∆32 mutation 
in blacks or persons of African origin. In this study none of the participant was either white or 
coloured and further to that in Zimbabwe marriages between black Zimbabweans and whites 
are generally rare, may be this is the reason why this gene was not detected in this study 
population.  
Although this study failed to detect any homozygous CCR5-∆32 gene in Harare, the gene 
might not be totally absent from the Zimbabwean population, as it is believed to be present in 
the Lemba tribe. This follows DNA research that has traced the Lemba’s origins to the Jews 
of the Middle East in Israel. Further to that a genetic marker largely found only in Cohanim, 
descendants of the ancient Jewish priesthood, is present in the same proportions among the 
Lemba’s own priests, known as the Buba (The Zimbabwean situation, 2010). The CCR5-∆32 
gene has a prevalence rate of between 20-35% among the Jews (Spinney, 2003). Because of 
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that the CCR5-∆32 gene might be present in the Lemba tribe of Zimbabwe, though this could 
not be detected in the current study because these people constitute less than 1% (80 000) of 
the Zimbabwean’s total population and are found about 700 km away from the study area 
(The Zimbabweansituation, 2010).  
5.2.3 Association between CCR264I and HIV infection 
The current study  re- affirm the suggestion that the distribution pattern of the rate and 
severity of the HIV epidemic may be indicative of greater underlying susceptibility to the 
virus in certain populations, which may be attributable to certain ubiquitous factors such as 
host genetics (Martinsoni, 1997). The reason for this is that the current study reports no 
protective traits in CCR2V64I gene and absent of CCR5-∆32 in the study population. The 
current findings have added more controversy in the debate surrounding the impact of CCR2 
on HIV infection, as CCR2V64I was associated with HIV infection (RR=2.321, 95% CI 
=1.376-3.916, p=0.002) in this study. Yet the majority of studies suggest that CCR2-64I, a 
conservative valine to isoleucine substitution in the transmembrane region, is associated with 
a significant delay in the progression to AIDS even in heterozygotes (Chakraborti & 
Banerjea, 2002; Kostrikis et al., 1998; Mulherin, O’Brien, Ioannidis, Goedert, Buchbinder,  
Coutinho, 2003).  
In agreement with the current study,  Singh and colleagues (2009) found that (homozygous  
CCR264I) CCR2-A/A genotype was associated with higher risk of vertical transmission vs G 
allele (CCR2 wild type) carriers suggesting a modest effect of CCR2 genotypes on Mother- 
To- Child- Transmission of HIV  in mother-infant pairs in sub-Sahara. Elsewhere,  a study to 
assess the association between perinatal HIV transmission and genetic polymorphism of 
chemokine co-receptors by Lousirirotchanakul and co-workers (2004) report a higher  
prevalence of CCR2 V64I gene  among infected children than in uninfected children (4% vs 
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1%)  in Thailand. In contrast to that, Mangano and collaborators (1998) observed the 
protective effect of CCR2-A/A (CCR2V64I/64I) genotype in Argentinean children born to 
HIV-1 infected mothers. On the other hand, Teglas and co-workers (1999) and Brouwer and 
group (2005) failed to find any impact of the CCR2 genotype on perinatal transmission in 
France and Western Kenya, respectively.  
The current study  suggest that, although CCR2 V64I gene has been reported to delay 
progression of HIV to AIDS, (Chakraborti & Banerjea, 2002; Kostrikis et al., 1998; 
Weissman et al., 1997, Mulherin et al., 2003; Christine, 2001), the gene may however, have 
some predisposal effect to HIV infection.  A number of host genes have been observed to 
exhibit similar characteristics as currently shown by the CCR2 V64I gene. For instance the 
Duffy Antigen Receptor for Chemokines -46C/C (DARC-46C/C) is associated with 40% 
increase in the odds of acquiring HIV-1, but once an individual is infected with HIV, those 
with the mutation live on average 2 years longer than those without it (He, Neil, Kulkarni,  
Wright,  Agan, Marconi et al.,  2008).   
The study design could have also affected the current results. The current study was a cross-
sectional study. In cross-sectional studies the determination of exposure and effect are made 
at the same time, as a result it is not easy to assess the reasons for associations shown. For 
instance a cross-sectional study, using a seroprevalent cohort rather than a cohort that 
followed individuals from the time of seroconversion, disputed the protective effect of 
CCR2V64I against HIV infection (Michael et al., 1997) just like our current study. Yet the 
majority of cohort studies seem to suggest that CCR2V64I gene delay progression of HIV to 
AIDS (Chakraborti & Banerjea, 2002; Kostrikis et al., 1998; Mulherin et al., 2003). On the 
other hand, high prevalence of CCR2V64I gene might be attributed to the fact that HIV 
infected people with the gene live longer (Chakraborti & Banerjea, 2002; Kostrikis et al., 
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1998; Mulherin et al., 2003), than those without the gene, as a result cross-sectional studies 
are bound to investigate those who are surviving leading to a rise in the number of infected 
people with the gene.  
5.2.4 Effect of confounders on the results 
 
There is compelling evidence that links STIs to HIV infection. Individuals who are infected 
with STIs are at least two to five times more likely than uninfected individuals to acquire 
HIV infection if they are exposed to the virus through sexual contact.  In addition to that, if 
an HIV-infected individual is also infected with another STIs, the person is more likely to 
transmit HIV through sexual contact than other HIV- infected persons (Munjoma, Kurewa, 
Mapingure, Mashavave, Chirenje, Rusakaniko et al., 2010; Centre for Disease and 
Prevention, 1992; Wasserheit, 1992).   Susceptibility to HIV infection in STIs infection 
occurs in two ways. Genital ulcers (syphilis, herpes, chancroid) result in the breaking of the 
genital tract lining or skin. These breaks create a portal of entry for HIV. In addition to this, 
inflammation resulting from genital ulcers or non-ulcerative STDs (trichomoniasis) increases 
the concentration of cells like CD4 -Tcells in genital secretions that can serve as targets for 
HIV (Centre for Disease and Prevention, 1992).  
In agreement with this, this study demonstrated that STIs were associated with HIV infection. 
Because of that we had to adjust for the confounding effect of these STIs in order to 
authentically measure the effect of CCR2 and CCR5 mutants on HIV transmission in the 
study population. We had therefore to use multivariate logistic regression analysis to adjust 
for the effect of the STIs. However, even after adjusting for the confounding effect of STIs, 
CCR2V64I gene continued to be associated with HIV infection among these pregnant 
women.  
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5.2.5 Study Limitations 
The current study used sera samples for DNA assays because this is what was available. Use 
of either plasma or whole blood could probably have given us better results, because the 
DNA content in some of the sera samples was very low. Because of this we ended up with a 
sample size of 242 instead of 288, though this was still within the statistical acceptable range 
of 138 to 288 participants calculated using a prevalence rate of 10-25% as observed by Matte 
and group (2001). Further to that, there may be other confounders like the nutritional status, 
immunological status and the number of sexual partners that could not be accounted for in 
this study. 
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CHAPTER 6: CONCLUSION 
 
The current study demonstrated that the homozygous CCR2V64I gene and STIs were 
prevalent in HIV infected pregnant mothers and was also associated with HIV infection in 
these pregnant women in Harare. Further to that the study found out that the homozygous 
CCR5-∆32 gene was absent in the same population. The study may  imply that African 
pregnant women in Epworth, St Mary’s and Seke North in Harare may be  more vulnerable to 
HIV-1 infection as they lack the protective effect conferred by the mutant form of CCR2 and 
CCR5 mutants, which block HIV-1 entry into the host cells or delays the progression of HIV 
to AIDS.  This finding further strengthens the observation       that the absence of the 
protective gene CCR5-∆32 and the observed predisposal effect of CCR2V64I genotype might 
have contributed to the accelerated spread of HIV in African populations ( Schliekelman et 
al., 2001; Sullivan et al., 2001). The current finding is a cause for public health concern in 
that CCR2V64I has a high frequency (13% to 25 %) among the African populations 
(Christine et al., 2001).  May be this partially explains the reason why Zimbabwe is rated 
among the top five countries hardest hit by the HIV pandemic in the world (UNAIDS, 
2008a). 
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CHAPTER 7: RECOMMENDATIONS 
 
 The observation that CCR2V64 gene is associated with HIV infection as well as the absent 
of CCR5-∆32 gene in the studied population is a cause for public health concern. Because of 
this further studies with a larger sample size should be carried out in Mberengwa district 
where we find the Lemba tribe who are said to be the descendents of the Israel Jews (The 
Zimbabweansituation, 2010) known to harbour both CCR2V64 and CCR5-∆32 genes 
(Spinney, 2003; Christine et al., 2001). Further to that the proposed study should also 
encompass investigation on the DARC -46C/C gene that could have influenced the current 
findings.  Conducting further studies is important because   information on the host genes to 
HIV infection remains useful in the designing of genetic polymorph targeted therapeutic 
interventions as well as for vaccine development. 
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APPENDICES 
Appendix 1: Record of English consent form 
 
RECORD OF INFORMED CONSENT  
Project title: HOST GENETIC FACTORS TO HIV INFECTION AMONG 
PREGNANT WOMEN FROM HARARE, ZIMBABWE  
 
Date:       ................................              
Interviewer: White Soko 
University of Western Cape Student no: 2706564 
Tel: 263 4700457-9/0912432752  Fax: 263 4253978 
E-mail: whitesoko@yahoo.co.uk 
Institution: National Institute of Health Research, Zimbabwe 
Place at which the samples will be stored and tested: University of Zimbabwe’s Medical school  
______________________________________________________________________ 
Thank you for agreeing to allow me to store and use your sample on Host genetic factors to 
HIV infection among mother-baby pairs. What follows is an explanation of the purpose and 
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process of this study. You are asked to give your consent to me so that I can store and conduct 
laboratory analyses of your sample to determine the role of the host genes to HIV transmission. 
 
1. Information about the researcher 
I am White Soko a student at the SOPH, University of the Western Cape. As part of my 
Masters in Public Health, I am required to conduct a research for use for the write up of my 
mini-thesis. I will be focusing on the Role of Host genes on HIV transmission in pregnant 
women. I am accountable to Prof M. Chirenje 791631 ex 2452 or by e-mail at chirenje@uz-
ucsf.co.zw  
Here is some information to explain the purpose and usage of your samples.  
2. Purpose of the study  
The purpose of this study is to determine the frequency of chemokine core receptors, CCR2-
V641 and CCR5 delta 32 genes and their association with HIV infection among pregnant 
mothers. The proposed study is expected to produce information on the key host genes that are 
involved in HIV transmission in the African population in Zimbabwe. Furthermore the 
information that is going to be produced will contribute to the understanding of the role  of  
CCR2-V641  and CCR5 delta 32 host genes, in the dynamics, evolution of the epidemic, and in 
designing effective chemotherapeutic drugs and vaccines directed against the chemokine core 
receptor sites. 
3. The data collection process 
Five (5) mls of stored serum samples from pregnant mothers who participated in the main study 
entitled “PREVENTION OF MOTHER TO CHILD TRANSMISSION OF SEXUALLY 
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TRANSMITTED INFECTIONS” now called “Better health for the African Mother and 
child” who consented to have their samples stored and used in this sub-study looking at the  
Frequency of host genetic factors to HIV infection among pregnant from Harare, will be used 
in testing for the chemokine receptor genes (CCR2V641 and CCR5 ∆ 32 genes). The HIV 
status of the samples will be drawn from the main register. 
4. Anonymity of contributors  
At all times, I will keep the source of the information confidential. To keep your information 
private, your samples will be labelled with a code/number that can only be traced back to 
your study clinic.  I shall keep any other records of your participation locked away at all 
times, and destroy them after the data has been collected. Your name, where you live, and 
other personal information will be protected by the study clinic.  When researchers are 
given your stored samples, they will not be given your personal information.  The 
results of future tests will not be included in your health records.  Every effort will be 
made to keep your personal information confidential, but we cannot guarantee absolute 
confidentiality.  Your personal information may be disclosed if required by law. 
5. Things that may affect your willingness to participate  
There are few risks related to storing your samples.  When tests are done on the stored 
samples there is a rare but possible risk to your privacy.  It is possible that if others 
found out information about you that is learned from tests (such as information about your 
genes) it could cause you problems with your family (having a family member learn about a 
disease that may be passed on in families) or problems getting a job or insurance. 
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If there is anything that you would prefer not to be done on your sample, please feel free to say 
so. I will not be offended and there will be no negative consequences if you would prefer not to 
answer a question. I would appreciate your guidance should I do anything which you see as 
intrusive.  
6. Agreement 
6.1 Interviewee's agreement 
The interviewee will be asked to give his/her consent below.  
6.2 Interviewer's agreement 
I shall keep the contents of the above research confidential in the sense that the codes noted 
above will be used in all documents which refer to the interview. The contents will be used for 
the purposes referred to above, but may be used for published or unpublished research at a later 
stage without further consent. Any change from this agreement will be renegotiated with you. 
 
Signed by interviewer: .............................. 
Signed by participant: ................................                                
Date:    ................................ 
Place:    ................................ 
Whom to contact if you have problems or questions 
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For questions about the storage and testing of your samples, contact:  
• The National Coordinator 
Medical Research Council of Zimbabwe 
National Institute of Health Research  
Cnr Mazoe Street/ Josiah Tongogara Avenue, Harare 
Ph +2634791792, 2634791193, Cell 263091433166 
• Principal  Investigator UZ/UNO 
Obstestrics and Gynaecology 
P.O Box A178 
Avondale 
Harare 
 
Tel: 2634791631 ex 2452 
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Appendix 2: Record of consent form Shona version 
 
RECORD OF INFORMED CONSENT  
Project title: HOST GENETIC FACTORS TO HIV INFECTION AMONG 
PREGNANT WOMEN FROM HARARE, ZIMBABWE  
 
Date:       ................................              
Researcher: White Soko 
University of Western Cape Student no: 2706564 
Tel: (04) 253975-9/ 0912432752 
  Fax: 263 4253978 
E-mail: whitesoko@yahoo.co.uk 
Institution: National Institute of Health Research, Zimbabwe 
Place at which the samples will be stored and tested: University of Zimbabwe’s Medical school  
TSANANGUDZO YECHIRONGWA 
Imi nemwana wenyu muri kukokwa kupinda muchirongwa chakanyorwa pamusoro chiri 
kuitwa neUniversity yedu yemuZimbabwe neyekuNorway chichitsigirwa neweLetten 
Foundation kuNorway zvakare. Kana mabvuma kupinda muchirongwa ichi, ropa rakatorwa 
muchirongwa chinonzi “PREVENTION OF MOTHER TO CHILD TRANSMISSION OF 
SEXUALLY TRANSMITTED INFECTIONS” chave kunzi  “Better health for the African 
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Mother and child richa shandiswa kuongorora  mahost genes anoti , CCR2-V641, ne  CCR5 
delata 32 genes. Tichawongorora wutachiwona hweHIV muropa iroro zve. Ropa rinoita 
mamiririta mashanu (5mls)  rakatorwa kwamuri amai, nemwana wenyu  rikachengetedzwa 
ndiro richashandiswa.  Sezvo ropa rakakosha, muri kukumbirwa kuti ropa iri 
rizoshandiswazve mune zvimwe zvirongwa zvemangwana kana chirongwa ichi chapera.  
Mune mibvunzo here pari zvino pane zvandatsanangudza. Kana mabvuma 
zvandatsanangudza pamusoro munoratidza nekusaina papepa rino.  
KUPINDA MUCHIRONGWA HAKUMANIKIDZWE 
Kubvuma kuti ropa renyu neremwana richengetedzwe hakumanikidzwi. Mune 
mvumo yekuti ropa renyu rigoshandiswe muchirongwa chino chete kana muchida 
uyezve mune mvumo yekuramba kuti ropa renyu rizoshandiswa mune zvimwe 
zvirongwa zvinotevera. 
Kunyange zvazvo mabvuma iye zvino kuti ropa renyu ringachengeterwa kushandiswa  mune 
zvimwe zvirongwa zvichatevera makasununguka kushandura pfungwa chero zvayo nguva. 
Kana izvi zvikaitika munofanira kuudza vashandi vechirongwa kuti mashandura pfungwa 
pamusoro peropa renyu rakachengetedzwa. Kana maramba kuti ropa renyu rizoshandiswa  
mune zvimwe zvirongwa zvichatevera rinoraswa panopera chirongwa chino. 
DONZO RECHIRONGWA 
Basa chairo rinoda kuitwa neropa renyu nderekuita ongororo dzechizvino-zvino. Ongororo 
yatirikuda kuita ndeyekuda kuona kuti pane zvinhu mumuviri yedu zvinonzi “mahost 
genes/HIV-1 chemokine receptor genes” zvino  batsiridza kana kudzivirira kutapurirwana 
kwe hutachiwona hweHIV-1. Izvi zvinoitwa kuti muongororwe kuti mune mhando (yema 
host genes/HIV-1 chemokine receptor genes) ipi yemachemokine receptors. Tinoda zvakare 
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kuona kuti machemokines amai akafanana kana kusiyana sei nemwana wavo.  Zvichabuda 
muongoro (maresults) zvichashandiswawo mukunyorwa kwegwaro (mini-thesis dissertation) 
reMasters  in Public Health. 
Hatina chinangwa chekukupai imi kana chiremba wenyu marizautsi eropa renyu 
rakachengetedzwa nokuti ongororo iyoyi haisati yakwenenzverwa zvinodiwa nemutemo. 
Vaongorori vechirongwa havana urongwa hwekuzivisa imi kana chiremba wenyu 
nezviwanikwa zvetsvagurudzo ino. Izvi zvinoitwa nokuti ongororo iyi inoitwa nenzira isati 
yanyatsokwenenzverwa zvinotarisirwa zvekuti marizautsi anogona kusakubatsirai kuita 
sarudzo ine chokuita nekuchengetedza utano hwenyu. Apo tinowana zvingange zvakakosha 
zvine chokuita neutano hwenyu, vaongorori vanozozivisa vashandi vechirongwa avo 
vanozokuzivisaiwo. Kana muchida kuzoziviswa nezviwanikwa zvakadai munofanira kuzivisa 
vashandi vechirongwa pamungazowanikwa. Kana muna chiremba wenyu wamunoda kuti 
azoziviswa nezviwanikwa zvakadai munofanirawo kupa vashandi vechirongwa 
pavanokwanisa kuwanira chiremba wenyu. 
Ropa renyu harizotengeswa kana kushandiswa kugadzira zvinowanisa mari. 
Mafambisirwo echirongwa achange achiongororwa newe Norwegian Ethical Review 
Committee pamwe chete nevanoona mafambisiro ezveongororo muZimbabwe, veMedical 
Research Council of Zimbabwe (MRCZ) 
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ZVICHAITWA 
Ropa rinoita mamiririta mashanu (5mls) rakatorwa kwamuri amai, nemwana wenyu  
rikachengetedzwa pa-86ºC kuUniversity yeZimbabwe department reObstetrics and 
Gynaecology,  ndiro richashandiswa kuongorora “machemokine coreceptor genes”. Vanhu 
vari kushanda muchirongwa ichochi chete ndivo vanobvumirwa kushandisa ropa renyu uye 
patubhotoro tweropa hatunyorwi zita renyu, asi panongoshandiswa nhamba chete. 
Naizvozvo vashandi ava havazivi zvachose kuti iri ropa nderaani. Ropa renyu 
ringangotumidzirwa kune vamwe vedu vatinoshandidzana nawo kuti riongororwe ikoko 
nemichina mitsva yemazuva ano yatisati tawanayo muno muZimbabwe. 
NJODZI/ MARWADZO 
Hapana njodzi inowanikwa mukuchengetedzwa nekuongororwa “machemokines coreceptor 
genes” kweropa renyu. Hazvinyanyoitika kuti mushandi arikuongorora ropa renyu 
rakachengetedzwa azive muridzi waro. 
ZVINGAKUBATSIRAI MUCHIRONGWA 
Hapana rubatsiro rwamunowana kubva muchirongwa chino kana kuchengetedzwa kweropa 
renyu. Asi zvichabuda muongororo zvichakubatsirai kuziva kuti mune mhando dzipi dzema 
chemokines receptor genes  uye izvi zvakakosha mushishi yekutsvagwa kwemishonga 
yokudzivirira chirerwe cheHIV usati waonekwa pari zvino. Imi kana vamwewo vane denda 
irori vangangobatsirikana mune remangwana kubva mune zvichabuda muongororo iyoyi. 
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KUCHENGETEDZWA KWEZVICHABUDA MUONGORORO 
Hapana zita renyu richashandiswa paongororo iyi asi tinoshandisa namba chete. Zita renyu, 
kero yenyu pamwe nezvimwe zvakabvunzwa pamusoro penyu zvichange zvakachengetedzwa. 
Vashandi wemuchirongwa vanoongorora ropa renyu havafi vakaziva zvinhu izvi. Zvinozobuda 
muzvirongwa zvemangwana hazvizonyorwi pakadhi renyu rekukiriniki. Zvinobvunzwa 
pamusoro peupenyu hwenyu , zita renyu  nezvichabuda muongororo yeropa hazvifi 
zvakaudzwa chero munhu zvake kunze kwevashoma vanoshanda muchirongwa ichi .Vane 
mvumo yekuona zita renyu pamwe chete nezviri pamusoro penyu ndeweMedical Research 
Council of Zimbabwe (MRCZ) sezvinotarisirwa pamutemo neveNorwegian Ethical 
Committee. 
Vavariro ichaitwa mukuedza kuchengetedza marekodzi pamwe nemarizautsi sezvinodiwa 
nemutemo.   
SIGNATURE PAGE 
CONSENT FOR SPECIMEN STORAGE AND SHIPMENT 
Nyatsoverengai zvakanyorwa pasi kana musingakwanisi kuverenga ndinokuverengarai 
munyatsoita sarudzo yamunoda pamusoro peropa renyu neongororo dzichaitwa pariri. 
Kuramba kwenyu hakushandure mabatirwo amunoitwa muchirongwa chekutanga.  
________ Ndinobvuma kuti ropa rangu neremwana wangu richengetedzwe, uye 
rizoshandiswa muzvirongwa zvemangwana zvine chekuita nedenda reHIV pamwe 
chete ne chemokine coreceptor gene testing.  
________ Ndinobvuma kuti ropa rangu neremwana wangu richengetedzwe, uye 
rizoshandiswa muzvirongwa zvemangwana zvine chekuita nedenda reHIV.  Asi 
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handibvumirani neongororo dzechemokine coreceptor gene testing kuti dziitwe 
paropa rangu neremwana wangu.  
________Handibvumi kuti ropa rangu neremwana wangu richengetedzwe uye rizoshandiswa 
muzvirongwa zvemangwana zvine chekuita nedenda reHIV.  
  ____________________________________ 
Participant Name (print)    Participant Signature or Mark and Date 
 
 
   ____________________________________ 
Study Staff Conducting    Study Staff Signature and Date 
Consent Discussion (print) 
 
 
 
   ____________________________________ 
Witness Name (print)    Witness Signature and Date 
(As appropriate) 
 
 
 
 
 
 
  
75 
 
 MIBVUNZO 
Kana mune mibvunzo yakanangana nekuchengetedzwa kweropa renyu, munogona kunyorera 
kana kuridza runhare   kuna  Prof M. Chirenje pakero inoti: 
• Principal  Investigator UZ/UNO 
Obstestrics and Gynaecology 
P.O Box A178 
Avondale 
Harare 
Tel: 2634791631 ex 2452, email: chirenje@uz-ucsf.co.zw 
• The National Coordinator 
Medical Research Council of Zimbabwe 
National Institute of Health Research  
Cnr Mazoe Street/ Josiah Tongogara Avenue 
Harare 
Ph 791792, 791193 
Cell 091433166 
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Appendix 3: Specifications of CCR5 Primers 
Primer                        Sequence Length   Tm GC 
content 
Sense Primer 
(Foward 
primer) 
5’-TTCATTACACCTgCAgCTCTC  21-mer  54.00C 47.6% 
Sense Primer 
(Reverse 
primer) 
5’-gACCAgCCCAAAgATgACTATC 22-mer 57.60C 54.5% 
 
Appendix 4: Specifications of CCR2 Primers 
 
Primer                        Sequence Length   Tm GC content 
Sense Primer 5’-TTCATTACACCTgCAgCTCTC  20-mer  54.30C 50.0% 
Antisense 5’-gACCAgCCCAAAgATgACTATC 20-mer 56.60C 50.0% 
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Appendix 5: Specifications of CCR2 Probes 
Probe 
name 
                       Sequence Length   Tm GC 
content 
CCR2 
Anchor 
5’-LC640-
CTgCAAAAAgCTgAAgTgCTTgACTg--PH 
 26-mer 64.30C 46.2% 
CCR2-
Sensor-mt 
5’-AACATgCTggTCATCCTCATCTTAATAA-
-FL 
28-mer 59.20C 35.7% 
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Appendix 6: Preparation of 2% agarose gel for analysis of PCR products 
1. Preparation of 1 % Agarose gel  
• 2 g agarose is weighed and 100 ml of TAE (1x) is added 
• Boil the mixtue for a few minutes, swirling occasionally to prevent boil over, until all 
the agarose is dissolved. 
• Let the solution cool to approximately  60.00C (until it is cool enough to hold the flask 
in your hand) 
• Add 1x SYBR safe solution 
• Pour the gel and insert the comb 
• After the gel has solidified the gel is put in the electrophoresis chamber filled with 
TAE (1x). 
• Remove the comb; the gel is now ready to load your DNA samples on. 
2. Loading of the gel 
• Remove 5 µl of your PCR product, add to it 3µl loading dye and load the gel. One 
well is used for a marker containing DNA of known size and quantity ( e.g 200bp) 
Electrophorese for approximately 1 hour at 80-100V . . After the electrophoresis the 
gel is submerged in a 0.5 to 1µg/ml Ethidiumbromide solution for about 20 to 30 
minutes. The DNA is visualised by UV  and a picture is taken.  
3. Reagents 
• Stock solution of TAE 50x: 
2M Tris (242g) 
1.66 M NaAc (136g) 
0.1M EDTA (37.2g) 
Stir till dissolved and add Acetic Acid up to a pH of 7.8. Add water up to 1 litre. 
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• Work solution of TAE 1x 
Dilute the TAE (50x) stock solution 1/50 with deionised water to a final concentration 
of:  
40mM Tris 
33 mM NaAc 
2mM EDTA 
• Loading dye 
40% sucrose 
0.2 % Bromophenol blue 
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Appendix 7: Procedure for the extraction of DNA from serum samples using the Boom  
et al., (1999) method. 
 
Reagents 
NucliSens Lysis Buffer 
NucliSens isolation kit, NucliSens 
Other Materials 
Microcentrifuge 
Centrifuge 
Screw-cap 1.5 ml microtube 
Dry heat temperature block 
Sterile Transfer Pipettes 
Dedicated fixes and variable pipettes tips 
Vortex mixer 
70% Ethanol 
Acetone 
Gloves 
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Method: 
Thaw Lysis Buffer Wash Buffer until all crystals have dissolved (about 30 minutes). 
Mix well. 
1. Add 0.1 ml plasma to 0.9 ml of Lysis Buffer in labelled screw-cap microtubes. 
Cap tightly and vortex briefly. 
2. Vortex silica thoroughly. Add 50 µl silica to each lysis tube, vortex and incubate 
10 minutes at room temperature. 
3. Quick spin lysis tubes, remove supernatant and 1,000 µl of Wash Buffer. Vortex 
thoroughly and quick spin. 
Repeat step 3 
4. Remove supernatant and add 1,000 µl of 70% Ethanol (made using 11 ml of 96% 
Ethanol and 4ml of distilled water). Vortex thoroughly and quick spin. Wash 
bench and change gloves. 
Repeat step 4 
5. Remove supernatant and add 1,000 µl of Acetone. Vortex and quick spin. Remove 
ALL the acetone. 
6. Dry silica/lysis tubes in a heat block at 560  C caps off for 10 minutes. (You may 
cover tubes with a paper towel). 
7.  Add 50 µl of Elution Buffer to each lysis/silica tube. Vortex  
8. Incubate  at  560   C , caps on, for a total of 10 minutes, vortexing after 5 minutes. 
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9. Spin lysis/silica tubes for 2 minutes at maximum speed (10,000 x g). 
For each specimen, remove 5 µl of supernatant to fresh, labelled micro tube. 
Avoid contaminating this aliquot with silica as silica can inhibit the amplification 
step. The rest of supernatant/silica should be kept at -700      C for up to a month. 
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Appendix 8: Standard procedure for real time PCR Amplification for CCR5 delta 32 
using the Applied Biosystems Step OneTM Plus Real-time PCR machine. 
Reagents preparation 
Stock Primers 
Reconstitute your primers by dissolving 5nmol lympolized primers into 0.5 mls of PCR grade 
distilled water in order to make a 10 nmol/ml l stock solutions. 
 
Dilution of stock solution to make a working solution of primers 
 
Make a 1:5 dilution of stock solution of both the forward and reverse primers sufficient 
enough to use in the preparation of master mix. 
 
 
Dilution of plasmids 
 
Make a 1: 10 000 dilution working solution of plasmids from the stock solution. 
 
Set up of reaction for one sample 
Reaction tube 
• In a 1.5ml reaction tube on ice, prepare the PCR mix for one 21 µl reaction by adding 
the following components 
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Syber green master mix       - 10 µl 
D32-F2 Primers    - 3 µl 
D32-R Primers    - 3 µl 
Template/Sample    - 5 µl (to be added in the capillary tube) 
Total volume     - 21 µl 
• Prepare the PCR master  mix for   more than one reaction, by multiply the amount by 
in “volume” by   column above  by Z, where Z = the  number  of reactions (samples) 
to be run + one addition reaction/sample.  
 
• Mix carefully by pipetting up and down. Do not vortex.  
 
Micro well plate 
• Pipet 15 µl PCR mix into each micro 96 well plate. 
• Add 5 µl of CCR5-∆32 and CCR5 plasmids as well as distilled water in duplicates. 
 
• Add 5 µl of the DNA template into each micro plate well. 
 
• Seal the micro plate  with a parafilm. 
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• Centrifuge the micro plate briefly in a micro-centrifuge. 
 
Amplification 
 
1. Place the samples in a Applied Biosystems Step One Plus Real-time PCR  machine to 
perform Forty cycles of amplification using the following temperature profiles: 
 
Stage 1: Activation of enzyme 
  Step 1: 950C for 10:0 minutes 
Stage 2: PCRx 40 cycles 
  Step1: 950C for 0:15s  
  Step 2: 600C for 1:00 minutes 
Stage 3:  Melting curve  
  Step 1: 950C for 0:15s 
  Step 2: 600C for 1:00 minute, then 0.30C/slope up to 950C  
  Step 3: 950C for 0:15s 
Measure the fluorescence light at 520 nm using a fluoremeter.  Amplicons containing the 32 
–bp deletion are supposed to have a melting temperature ( Tm  ) that is approximately 20C 
lower than that of the 83 bp.  
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Appendix 9: Standard procedure for real time PCR Amplification  for CCR2V64I  on a 
LightCycler 
REAGENTS PREPARATION 
Primers and oligoprobes 
1. Reconstitute primers by dissolving 5nmol in 0.5ml of PCR grade water to make a 
concentration of a 10 nmol/ml  
2. Reconstitute the probes  by  dissolving 1mmol in 0.5 mmol of PCR grade water to 
make a concentration of 2nmol/ml  
 
Set up of reaction for one sample  
• Do not touch the surface of the capillaries. Always wear gloves when handling the 
capillaries. For volumes <20 µl, the reaction and cycles conditions must be optimized. 
• Depending on the total number of reactions, place the required number of LightCycler  
Capillaries in pre-cooled  centrifuge adapters or in a LightCycler Sample Carousel in 
precooled LC Carousel Centrifuge Bucket. 
• Thaw the solutions and, for maximal recovery of contents, briefly spin vials in a 
microcentrifuge before opening. Mix carefully by pipetting up and down and store on 
ice. 
• Prepare a 10 X conc. solution of PCR primers by and a 10 X conc. solution of 
HybProbe probes. 
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• In a 1.5 reaction tube on ice, prepare the PCR mix for one 20 µl reaction by adding 
the following components 
3mM  MgCl2        concentration master mix recipe for the master mix 
PCR AMPLIFICATION MASTER MIX (for 25µl reaction volume) 
 
Hyb Prob EnzymeMaster mix  - 2 µl 
MgCl2      - 1.6 µl 
CCR2-F Primers   - 2 µl 
CCR2-R Primers   - 2 µl 
CCR2 Sensor Probe   - 2 µl 
CCR2 Anchor Probe   - 2 µl 
DNATemplate   - 5 µl 
PCR Distilled Water   - 3.4 µl 
Total volume    - 20 µl 
 
• Prepare the PCR master  mix for   more than one reaction, by multiply the amount by 
in “volume” by   column above  by Z, where Z = the  number  of reactions (samples) 
to be run + one addition reaction/sample.  
• Mix carefully by pipetting up and down. Do not vortex.  
 
 
 
 
  
88 
 
• Centrifuge sample capillaries in a LC Carousel Centrifuge Bucket. 
 
Amplification 
3. Place the samples in a Light Cycler machine 
4. Perform a 2 min denaturation at 95 0 C. 
5. Perform the 45 cycles of amplification using the following temperature profile: 
Denaturation  95 0 C, for 0 s 
 
Primer annealing 640 C for 15 s 
 
Primer extension 720 C for 25 s 
 
6. Conduct a melting curve determination as follows: 
(With a 0.2/sec slope from 45 0 C to 950 C)  
95 0 C for 20 s 
64 0 C for 25 s 
58 0 C for 25 s 
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7. Measure the fluorescence light using channels F2 (640nm) and F1 (520 nm) in a 
fluoremeter. 
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Appendix 10: Sequence of the CCR5 wt negative control plasmids  
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Appendix 11: Sequence of CCR5∆32 positive control plasmids   
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Appendix 12: Sequence of CCR2 64V negative control plasmids  
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Appendix 13: Sequence of CCR2 64I positive control plasmids for CCR2V64I gene 
 
  
 
 
 
 
